Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Travanti Pharma Inc.

Division of Teikoku Seiyaku Co. Ltd.
www.travantipharma.com

Latest From Travanti Pharma Inc.

Bayer leads new €20m consortium aiming to optimize drug design

Bayer HealthCare and Leiden University of the Netherlands are set to co-ordinate a newly founded international consortium comprising 20 partners, with the aim of optimizing drug design to reduce the rate of failure in clinical trials. The consortium is backed by Europe's Innovative Medicines Initiative (IMI), which has given €20 million in funding.

United Kingdom

Astellas and Merck Serono join new alliance for bilharzia in young children

Major Japanese firms are continuing to build up their activities in the neglected diseases area, with Astellas becoming the latest to take part in a new project to treat schistosomiasis in preschool age children.

Cardiovascular Infectious Diseases

The Netherlands to invest €28 million in personalised medicines

Three Netherlands public-private partnerships are to invest €28 million into the development of personalised medicines. BioMedical Materials (BMM), the Center for Translational Molecular Medicine (CTMM) and the Top Institute Pharma (TI Pharma) have a combined budget of almost €700 million, to which the Dutch government is contributing half.

Cancer Netherlands

Transatlantic tensions and the R&D debate

On September 14th, Europe's Innovative Medicines Initiative, which aims to find ways of streamlining the drug development process, will hold a press conference to present its achievements to date. Approved at the end of December 2007, the IMI is a joint effort between the EU and the European industry federation EFPIA that is expected to improve the productivity of pharmaceutical and biotech R&D and give companies a keener competitive edge.

See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
  • Therapeutic Areas
  • Alias(es)
  • Birch Point Medical Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Teikoku Seiyaku Co. Ltd.
  • Senior Management
  • Robert Z Arnold, VP, Mktg., Sales & Bus. Dev.
  • Contact Info
  • Travanti Pharma Inc.
    Phone: (651) 730-1008
    2520 Pilot Knob Rd.
    Ste. 100
    Mendota Heights, MN 55120
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register